A Biotechnology Company Focused on Rare Brain Tumors such as Neurofibromatosis 2 (NF2)

Bringing Effective Therapies to Patients with Rare Brain/Nervous System Cancers

A clinical-stage biopharmaceutical company focused on bringing effective therapies targeted at rare cancers to patients. The most advanced clinical program at CereXis is for patients with Neurofibromatosis type 2, an autosomal dominant syndrome characterized by multiple tumors of the nervous system, especially in the brain and spinal cord.